

**DAFTAR PUSTAKA**

- Adeboyeje, G., Sylwestrzak, G., Barron, J. J., White, J., Rosenberg, A., Abarca, J., Redberg, R. 2017. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. **Journal of Managed Care & Specialty Pharmacy**, Vol. 23, No. 9, p. 968–978.
- Agrawal, H., Aggarwal, Kul., Littrell, R., Velagapudi, P., Turagam, Mohit K., Mittal, M., Alpert, Martin A. 2015. Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease. **Current Cardiology Reviews**, Vol. 11, No. 3, p. 261-269.
- Al-Nozha, M. M., Ismail, H. M., & Al Nozha, O. M. 2016. Coronary artery disease and diabetes mellitus. **Journal of Taibah University Medical Sciences**, Vol.11, No. 4, p. 330–338.
- Alban, S. 2011. Adverse Effects of Heparin. **Handbook of Experimental Pharmacology**, p.211–263.
- Anderson, J, L., Adams, C, D., Antman, E, M., Bridges, C, R., Califf, R, M., Casey, D, E., Chavey, W, E., Fesmire, F, M., Hochman, J, S., Levin, T, N., Lincoff, A, M., Peterson, E, D., Theroux, P., Wenger, N, K., Wright. R, Scott., 2013, Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology.**, Vol. 61, No. 23. p. e179-347.
- Aslanabadi, N., Safaie, N., Talebi, F., Dousti, S., dan Entezari-Maleki, T. 2018. The Streptokinase Therapy Complications and Its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction. **Iran J Pharm Res**. Vol. 17, p. 53-63.
- Baluwala, Israfil., Favalaro, Emmanuel., & Pasalic, Leonardo. 2017. Therapeutic Monitoring of Unfractionated Heparin – Trials and Tribulations. **Expert Review of Hematology Journal**, Vol. 10, No. 7, p. 595-605.

- Balon, R., Rafanelli, C., & Sonino, N. 2018. Benzodiazepines: A Valuable Tool in the Management of Cardiovascular Conditions. **Psychotherapy and Psychosomatics**, p. 1–4.
- Bassand, J.P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Francisco F.A., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W. 2007. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes. **European Heart Journal.**, Vol. 28, No. 13, p. 1598-1660.
- Bittner, V. 2005. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. **Journal of the American College of Cardiology**, Vol.46, No.9, p. 1628–1635.
- Brieger, David. 2012. Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome. **The American Journal Cardiology.**, Vol. 110, p. 1200-1206.
- Bruins Slot, K. M., & Berge, E. 2018. Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation. **Cochrane Database of Systematic Reviews**. doi:10.1002/14651858.
- Burstein, Barry., Wieruszewski, Patrick, M., Zhao, Yan-Jun., Smischney, Nathan. 2019. Anticoagulation with Direct Thrombin Inhibitors during Extracorporeal Membrane Oxygenation. **World Journal of Critical Care Medicine**, Vol 8, No.6, p: 87-98.
- Chan, Anthony, K, C., & Paredes, Nethnapha. 2013. The Coagulation System in Humans. **Methods in Molecular Biology**, Vol. 992, p. 3-12, New York.
- Clayville, L. R., Anderson, K. V., Miller, S. A., & St Onge, E. L. 2011. New options in anticoagulation for the prevention of venous thromboembolism and stroke. **P & T : a peer-reviewed journal for formulary management**, Vol 36, No.2, p. 86–99.
- Cossette, B., Pelletier, M. E., Carrier, N., Turgeon, M., Leclair, C., Charron, P., Farand, P. 2010. Evaluation of Bleeding Risk in Patients Exposed to Therapeutic Unfractionated or Low-Molecular-Weight Heparin: A Cohort Study in the Context of a Quality Improvement Initiative. **Annals of Pharmacotherapy**, Vol. 44, p.994–1002.
- De Lemos, James, A., & Omland, Torbjørn. 2018, **Chronic Coronary Artery Disease**, Philadelphia: Elsevier. p. 1-498.

- Dipiro, Joseph T., Talbert, Robert L., Yee, Gary C., Matzke, Gary A., Wells, Barbara G., Posey, L. Michael. 2019. **Pharmacotherapy A Pathophysiologic Approach 10<sup>th</sup> Edition**, USA : McGraw – Hill Companies. p. 761-826.
- Dobesh, Paul P. 2019. Stable Ischemic Heart Disease. *In*: Dipiro, Joseph T., Talbert, Robert L., Yee, Gary C., Matzke, Gary A., Wells, Barbara G., Posey, L. Michael. 2019, **Pharmacotherapy A Pathophysiologic Approach 10<sup>th</sup> Edition**, USA : McGraw – Hill Companies. p. 691-760
- Dobesh, P. P., & Oestreich, J. H. 2014. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. **Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy**, Vol. 34, No. 10, p. 1077–1090.
- Fu, L., Zhang, F., Li, G., Onishi, A., Bhaskar, U., Sun, P., & Linhardt, R. J. 2014. Structure and Activity of a New Low-Molecular-Weight Heparin Produced by Enzymatic Ultrafiltration. **Journal of Pharmaceutical Sciences**, Vol. 103(5), p. 1375–1383.
- Gebauer, M. 2007. Synthesis and Structure–Activity Relationships of Novel Warfarin Derivatives. **Bioorganic & Medicinal Chemistry**, Vol. 15, No.6, p. 2414–2420.
- Gersh, Bernard J., White, Harvey D., Opie, Lionel H., 2013, Antithrombotic agents : Platelet Inhibitors, anticoagulants, and fibrinolytics, *In* :Gersh, Bernard J., Opie, Lionel H., **Drug for The Heart 8<sup>th</sup> ed**, USA : Elsevier, p. 291-297.
- Göbel, K., Eichler, S., Wiendl, H., Chavakis, T., Kleinschnitz, C., & Meuth, S. G. 2018. The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review. **Frontiers in Immunology**, Vol. 9.
- Guyton A. C., & Hall J. E., 2010, **Textbook of Medical Physiology (12 ed.)**, New York: Elsevier.
- Hamm, Christian W., Bassand, Jean-Pierre., Agewall, Stefan., Bax Jeroen., Boersma, Eric., Bueno, Hector., Caso, Pio., Dudek, Dariusz., Gielen, Stephan., Huber, Kurt., Ohman, Magnus., Petrie, Mark C., Sonntag, Frank., Uva, Miguel Sousa., Storey, Robert F., Wijn, William., Zahger, Doron., 2011. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment

- elevation of the European Society of Cardiology (ESC), **European Heart Journal**, Vol. 32, p. 2999-3054.
- Harter, Katherine, Levine., Michael, Henderson., Sean, O., 2015. Anticoagulation Drug Therapy: A Review. **Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health**, Vol 16, No.1, pp: 11-17.
- Herdaningsih, S., Muhtadi, A., Lestari, K., Annisa, N., 2016. Potensi Interaksi Obat-Obat pada Resep Polifarmasi: Studi Retrospektif pada Salah Satu Apotek di Kota Bandung. **Jurnal Farmasi Klinik Indonesia**, Vol. 5, No. 4, p. 288-292.
- Hirsh, Jack., Warkentin, Theodore E., Shaughnessy, Stephen G., Anand, Sonia S., Halperin, Jonathan L., Raschke, Robert., Granger, Christopher., Ohman, E. Magnus., Dalen, James E., 2001, Heparin and Low-Molecular Weight Heparin : Mechanism of action, pharmacokinaetics, dosing, monitoring, efficacy, and safety, **Sixth ACCP Consensus Conference on Antithrombotic Therapy**, p. 64-94.
- Hoffman, Maureane., 2010. Heparins: Clinical Use and Laboratory Monitoring. **Laboratory Medicine**, Vol. 41, p. 621-626.
- Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., ... Palesch, Y. Y. 2018. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. **New England Journal of Medicine**, Vol.379, No. 3, p. 215–225.
- Kulkarni, Suhasini., Dopheide, Sacha, M., Yap, Cindy, L., Ravanat, Catherine., Freund, Monique., Mangin, Pierre., Heel, Kathryn, A., Street, Alison., Harper, Ian. S., Lanza, Francois., Jackson, Shaun, P., 2000. A Revised Model of Platelet Aggregation. **The Journal of Clinical Investigation**, Vol. 105, No. 6, pp 783–791.
- Layne, Kerry., & Ferro, Albert. 2017. Antiplatelet Therapy in Acute Coronary Syndrome. **European Cardiology Review Journal**, Vol. 12, No. 1, p. 33-37.
- Lee, C. J., & Ansell, J. E. 2011. Direct thrombin inhibitors. **British Journal of Clinical Pharmacology**, Vol.72, p.581–592.
- Libby, Peter., & Theroux, Pierre., 2005. Pathophysiology of Coronary Artery Disease. **Circulation American Heart Association Journal**. Vol. 111, p. 3481-3488.
- Mahalle, N., Garg, M., Naik, S., & Kulkarni, M. 2014. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven

- coronary artery disease. **Indian Journal of Endocrinology and Metabolism**, Vol.18, No. 1, p. 48-55.
- Mehta, S, R., Granger, C, B., Eikelboom, J, W., Bassand, J.P., Wallentin, L., Faxon, D, P., Peters, R, J, G., Budaj A., Afzal, R., Chrolavicius, S., Fox, K, A, A., Yusuf, S., 2013, Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. **Journal of the American College of Cardiology.**, Vol. 50, No. 18. Elsevier Inc. p. 1742-1751.
- Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., ... White, H. 2011. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium. **Circulation**, Vol. 123, p. 2736–2747.
- Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E. 2015. New Oral Anticoagulants: Their Advantages and Disadvantages Compared with Vitamin K Antagonists in The Prevention and Treatment of Patients with Thromboembolic Events. **Therapeutics and Clinical Risk Management**, Vol. 11, p. 967-977.
- Messner, B., Bernhard, D. 2014. Smoking and Cardiovascular Disease: Mechanisms of Endothelial Dysfunction and Early Atherogenesis. **Arteriosclerosis, Thrombosis, and Vascular Biology**, Vol. 34, No. 3, p. 509-515.
- Milling, T. J., Clark, C. L., Feronti, C., Song, S. S., Torbati, S. S., Fermann, G. J., Patel, D. 2018. Management of Factor Xa Inhibitor-Associated Life-Threatening Major Hemorrhage: A Retrospective Multi-Center Analysis. **The American Journal of Emergency Medicine**, Vol. 36, p.396–402.
- Misnah., Abdullah, Agus Alim., Arif, Mansyur., Bahar, Burhanuddin. 2012. Pemeriksaan Prothombin Time Dan Activated Partial Thromboplastin Time Dengan Humaclot VA Serta Sysmex CA 500. **Indonesian Journal Of Clinical Pathology And Medical Laboratory**, Vol. 18, No. 3, p. 147-210.
- Mosca, L., Barrett-Connor, E., Wenger, N K. 2011. Sex/Gender Differences in Cardiovascular Disease Prevention What a Difference a Decade Makes. **Circulation American Heart Association**, Vol. 124, No. 19 p. 2145–2154
- Nutescu, E. A., Burnett, A., Fanikos, J., Spinler, S., & Wittkowsky, A. 2016. Pharmacology of Anticoagulants Used in The Treatment of Venous Thromboembolism. **Journal of Thrombosis and Thrombolysis**, Vol. 41, p. 15-31.

- Nuti, S Venkata., Desai, N., Wang, S., Li, Jing., Wang, Y., Spertus, J., Masoudi, F., Krumholz, H., Jiang, Lixin. 2014. Trends in the Prevalence and Outcomes of NSTEMI and STEMI among Patients with Acute Myocardial Infarction in China from 2001 to 2011: China PEACE Retrospective AMI Study. *American College Cardiology*, Vol. 63, No. 12.
- Onwordi, E. N., Gamal, A., & Zaman, A., 2018. Anticoagulant Therapy For Acute Coronary Syndromes. **Interventional Cardiology Review**, Vol. 13, p. 87-92.
- Palta, S., Saroa, R., & Palta, A. 2014. Overview of the coagulation system. **Indian Journal of Anaesthesia**, Vol. 58, p.515-523.
- PERKI., 2015. **Pedoman Tatalaksana Sindrom Koroner Akut**, Indonesia: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Periayah, M, H., Halim, A, S., Mat Saad, A, Z. 2017. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. **International Journal of Hematology-Oncology and Stem Cell Research**, Vol. 11, No. 4.
- Piran, S., & Schulman, S. 2018. Treatment of bleeding complications in patients on anticoagulant therapy. *Blood Journal*, Vol. 133, No. 5, p. 425-435.
- Ponert, J, Moritz., Gockel, L, Maria., Henze, Svenja., Schlesinger, Martin., 2018. Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells. **Molecules Journal**, Vol 23, pp 2690.
- Puymirat, E., Aissaoui, N., Collet, Jean-Philippe., Chaib, A., Bonnet, Jean-Louis., Bataille, V., Drouet, E., Mulak, G., Ferrieres, J., Didier, B., Tabassome, S., Danchin, N., 2013, Comparisson of bleeding complications and one-year survival of low molecular weight heparin versus unfractionated heparin for acute myocardial infarction in elderly patients, **International Journal of Cardiology**, 166, p. 106-110.
- Riskesdas (Riset Kesehatan Dasar). 2018. *Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI*. (diakses pada tanggal 4 Desember 2019).
- Roberts, A., Dager, W., & Van Cott, E. 2017. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors. **Seminars in Thrombosis and Hemostasis**, Vol. 43, p. 270–276.
- Roffi, Marco., Patrono, Carlo., Collet, Jean-Philippe., Mueller, Christian., Valgimigli, Marco., Andreotti, Felicita., Bax, Jeroen J., Borge, Michael A., Brotons,

- Carlos., Chew, Derek P., Gencer, Baris., Hasenfuss, Gerd., Kjeldsen, Keld., Lancellotti, Patrizio., Landmesser, Ulf., Mehilli, Julinda., Mukherjee, Debabrata., Storey, Robert F., Windecker, Stephan., 2016. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). **European Heart Journal.**, Vol. 37, pp. 267–315.
- Rogers, Kelly C., Denu, de Simon., Finks, Shannon W., Spinler, Sarah A., 2019. Acute Coronary Syndromes. *In*: Dipiro, Joseph T., Talbert, Robert L., Yee, Gary C., Matzke, Gary A., Wells, Barbara G., Posey, L. Michael., 2019, **Pharmacotherapy A Pathophysiologic Approach 10<sup>th</sup> Edition**, USA : McGraw – Hill Companies.
- Rognoni, Andrea., Cavallino, Chiara., Veia, Alessia., Bacchini, Sara., Rosso, Roberta., Facchini, Manuel., Secco, Gioel G., Lupi, Alessandro., Nardi, Federico., Rametta, Francesco., Bongo. Angelo S., 2015. Pathophysiology of Atherosclerotic Plaque Development. **Cardiovascular & Hematological Agents in Medicinal Chemistry.**, Vol. 13, No. 11, p. 10-13.
- Scanlon, Valerie C., & Sanders, Tina., 2007, **Essential of Anatomy and Physiology**, Philadelphia: F. A. Davis Company.
- Smith, S. A., Travers, R. J., & Morrissey, J. H. 2015. How it all starts: Initiation of the clotting cascade. **Critical Reviews in Biochemistry and Molecular Biology**, Vol. 50, No. 4, p. 326–336.
- Summers, Katherine, L., Davis, Kyle, A., Nisly, Sarah, A., 2019. Bleeding Risk of Therapeutic Unfractionated Heparin and Low Molecular Weight Heparin in Patients with Cirrhosis. **Clinical Drug Investigation**.
- Samama, Meyer-Michel., Gerotziafas, Grigoris T., 2002. Evaluation Of The Pharmacological Properties And Clinical Results Of The Synthetic Pentasaccharide (fondaparinux). **Thrombosis Research**, Vol. 109, p. 1 – 11.
- Stockley., Baxter, K., 2010. **Stockley's Drug Interactions: 9th Edition**. Pharmaceutical Pr, London.
- Talbert, Robert L., 2008. Ischemic Heart Disease. *In*: Dipiro, Joseph T., Talbert, Robert L., Yee, Gary C., Matzke, Gary A., Wells, Barbara G., Posey, L. Michael., 2008,

- Pharmacotherapy A Pathophysiologic Approach 7<sup>th</sup> Edition**, USA : McGraw – Hill Companies, p. 217-243.
- Tickoo, S., Bhardwaj, A., Fonarow, Gregg C., Liang, Li., Bhatt, Deepak L., Cannon, Christopher P. 2016. Relationship Between Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes. **The American Journal of Cardiology**, Vol. 117, No. 2, p. 201–205.
- Tideman, P. A., Tirimacco, R., St John, A., & Roberts, G. W. 2015. How to manage warfarin therapy. **Australian Prescriber**, Vol. 38(2), p. 44–48.
- Trailokya, Abhijit., Dhall, Anil., Kumbla, DK., 2015. Fondaparinux in Acute Coronary Syndromes. **Journal of The Association of Physicians of India.**, Vol. 63, p. 83-87
- Tubaro, M., Vranckx, P., Price, S., Vrints, C., 2018. The ESC Textbook of Intensive and Acute Cardiovascular Care (2 ed.), **European Society of Cardiology**, p. 1-43.
- Vivian, Ng, G., Baumbach, A., Grinfeld, L., Lincoff, A. M., Mehran, R., Stone, G. W., & Lansky, A. J. 2016. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). **The American Journal of Cardiology**, Vol. 117, No. 2, p. 186–191.
- Weber, T., Lang, I., Zweiker, R., Horn, S., Wenzel, R. R., Watschinger, B., Metzler, B. 2016. Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. **Wiener Klinische Wochenschrift**, Vol. 128, No. 13-14, p. 467–479.
- Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. 2016. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. **Journal of Thrombosis and Thrombolysis**, Vol. 41, No. 1, p. 187–205.
- Witt, Daniel M., Clark, Nathan P., Vazquez, Sara R., 2019. Venous Thromboembolism. *In*: Dipiro, Joseph T., Talbert, Robert L., Yee, Gary C., Matzke, Gary A., Wells, Barbara G., Posey, L. Michael., 2019, **Pharmacotherapy A Pathophysiologic Approach 10<sup>th</sup> Edition**, USA : McGraw – Hill Companies, p. 912-986.
- Wu, C, K., Juang, J, M, J., Chiang, J, Y., Li, Y, H., Tsai, C, T., Chiang, F,T., 2018, The Taiwan Heart Registries: Its Influence on Cardiovascular Patient Care. **Journal of The American College of Cardiology.**, Vol. 71, No. 11. p. 1273-1283.



- Wu, S., Chen, X., Jin, D.-Y., Stafford, D. W., Pedersen, L. G., & Tie, J.-K. 2018. Warfarin and Vitamin K Epoxide Reductase: a Molecular Accounting for Observed Inhibition. **Blood Journal**. p. 1-30.
- Yeh, C. H., Hogg, K., & Weitz, J. I. 2015. Overview of the New Oral Anticoagulants: Opportunities and Challenges. **Arteriosclerosis, Thrombosis, and Vascular Biology**, Vol. 35, No.5, p. 1056–1065.
- Zehnder, J.L., 2012. Obat yang Digunakan pada Gangguan Koagulasi. In: B,G, Katzung (Ed). **Farmakologi Dasar dan Klinik**, Ed 12<sup>th</sup>, Indonesia: McGraw-Hill Companies Inc., pp 675-696.
- Zhou, Q., Chen, M., Zhu, L., Yu, L., Zeng, S., Xiang, M., & Wang, Z.-Y. 2015. Pharmacokinetic Drug Interactions With Clopidogrel: Updated Review And Risk Management In Combination Therapy. **Therapeutics and Clinical Risk Management**, p.449-467.